JAVELIN Bladder 100 Trial

Background

Phase III RCT of 700 patients with unresectable locally advanced or metastatic urothelial carcinoma whose disease had not progressed after 4-6 cycles of first-line gemcitabine plus a platinum agent. Patients were randomized to maintenance therapy.

Interventions and follow up

Arm A: Maintenance avelumab 10 mg/kg IV q2wk plus best supportive care until progression, toxicity, or withdrawal
Arm B: Best supportive care alone
Primary endpoint: Overall survival (overall population and PD-L1-positive population)
Median follow up: >19 mo

Results

Overall mOS: 21.4 mo vs 14.3 mo (A vs B); HR 0.69, 95% CI 0.56-0.86; P=.001
Overall 1-yr OS: 71.3% vs 58.4%
PD-L1+ mOS: NR vs 17.1 mo; HR 0.56, 95% CI 0.40-0.79; P<.001
PD-L1+ 1-yr OS: 79.1% vs 60.4%
PD-L1- mOS: 18.8 mo vs 13.7 mo; HR 0.85, 95% CI 0.62-1.18

Adverse events

Grade 3 or higher events: 47.4% vs 25.2% (A vs B)
Constitutional/skin: Fatigue 17.7% vs 7%; pruritus 17.2% vs 1.7%
Infection: Urinary tract infection 17.2% vs 10.4%

Conclusions

Maintenance avelumab significantly prolonged overall survival in patients with advanced urothelial carcinoma who had not progressed on first-line platinum-based chemotherapy, with the largest benefit in PD-L1-positive disease. PD-L1+ defined per the SP263 assay (≥25% tumor cells, or ≥25% tumor-associated immune cells when immune cells >1%, or 100% of immune cells when immune cells ≤1%).

Key Limitations

Control arm received no maintenance therapy. Predates first-line enfortumab vedotin plus pembrolizumab, which has reshaped frontline standards and the role of switch-maintenance immunotherapy.

Clinical Context

JAVELIN Bladder 100 led to FDA (2020) and EMA approval of avelumab as first-line maintenance therapy in advanced urothelial carcinoma without progression on platinum chemotherapy, establishing it as an ASCO/ESMO-supported standard. Its role is now weighed against frontline enfortumab vedotin plus pembrolizumab.

References